8-K/A filed June 25, 2024, 7:59 PM ET ticker BHIC CIK 0001784440

M&A confidence high sentiment neutral materiality 0.80

BioScience Health Innovations, Inc. (BHIC): M&A transaction — Nowtransit completes reverse merger with Best Labs; issues 34M shares (85.4%) for supplement business

BioScience Health Innovations, Inc.

Issued 34,371,100 shares (85.39% of post-closing shares) to Best Labs shareholders for all of Best's shares; deal closed March 10, 2023.
Company exited online delivery business; now markets Be On-Guard mouth spray, nasal spray, surface cleaner, brain support supplements, and methylene blue products.
Zero employees as of March 13, 2023; supply chain managed by Ageless Holdings LLC (CEO is managing member).
Filing addresses shell status; company remains OTC Pink voluntary filer, subject to penny stock rules and limited liquidity.
Holds provisional patent 63/560,474 for methylthioninium salt compositions; plans to file PCT application by March 2024.

item 1.01 item 2.01 item 5.03 item 9.01 item 4.01 item 3.02 item 5.02 item 5.06

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Darren Lopez

Director

BHIC · BioScience Health Innovations, Inc.

Filed: June 25, 2024, 7:59 PM ET

Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors with Justin Earl.

Departed

Justin Earl

Chief Executive Officer

BHIC · BioScience Health Innovations, Inc.

Successor: Darren Lopez
Filed: June 25, 2024, 7:59 PM ET

Justin Earl tendered his resignation as the sole officer of the Company.

Appointed

John Chymboryk

Director

BHIC · BioScience Health Innovations, Inc.

Filed: June 25, 2024, 7:59 PM ET

Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors with Justin Earl.

Appointed

Darren Lopez

Chief Executive Officer

BHIC · BioScience Health Innovations, Inc.

Filed: June 25, 2024, 7:59 PM ET

Darren López was appointed as the Chief Executive Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Darren Lopez was appointed as Director at BioScience Health Innovations, Inc..

Action: appointed
Role: Director

Exact text from the filing

Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors with Justin Earl.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Justin Earl resigned as Chief Executive Officer at BioScience Health Innovations, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Justin Earl tendered his resignation as the sole officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Chymboryk was appointed as Director at BioScience Health Innovations, Inc..

Action: appointed
Role: Director

Exact text from the filing

Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors with Justin Earl.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Darren Lopez was appointed as Chief Executive Officer at BioScience Health Innovations, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Darren López was appointed as the Chief Executive Officer of the Company.

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.98

BioScience Health Innovations, Inc. completed an acquisition involving Best Labs, Inc. for 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares (closed 2023-03-10).

Action: acquisition
Counterparty: Best Labs, Inc.
Consideration: 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares
Closing: 2023-03-10

Exact text from the filing

2023 (the “ Closing ”). As a result of the Exchange Agreement Best became the wholly-owned subsidiary of the Company. Upon the Closing, the Company issued the Best shareholders 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares of the Company’s common stock following Closing, in exchange for all

View on SEC.gov

78 m&a transactions filed in the last 30 days. Browse all m&a transactions →

BioScience Health Innovations, Inc. filing history →

Source: SEC EDGAR

accession 0001185185-24-000654

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.